

Kosh Agarwal

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4671890/kosh-agarwal-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237
papers

18,365
citations

52
h-index

134
g-index

294
ext. papers

22,260
ext. citations

8.6
avg, IF

6.75
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 237 | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017 , 67, 370-398 | 13.4 | 2354 |
| 236 | Telaprevir for previously untreated chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , 2011 , 364, 2405-16 | 59.2 | 2004 |
| 235 | Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2014 , 370, 1889-98 | 59.2 | 1402 |
| 234 | EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511 | 13.4 | 1079 |
| 233 | Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. <i>New England Journal of Medicine</i> , 2009 , 360, 1839-50 | 59.2 | 897 |
| 232 | Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2599-607 | 59.2 | 758 |
| 231 | ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. <i>New England Journal of Medicine</i> , 2014 , 370, 1973-82 | 59.2 | 754 |
| 230 | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2608-17 | 59.2 | 613 |
| 229 | Natural history of hepatitis C. <i>Journal of Hepatology</i> , 2014 , 61, S58-68 | 13.4 | 524 |
| 228 | Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2016 , 16, 685-697 | 25.5 | 346 |
| 227 | Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2016 , 64, 1224-31 | 13.4 | 344 |
| 226 | Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2016 , 65, 741-747 | 13.4 | 278 |
| 225 | EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218 | 13.4 | 237 |
| 224 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 185-195 | 18.8 | 237 |
| 223 | Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. <i>Journal of Hepatology</i> , 2017 , 67, 263-271 | 13.4 | 218 |
| 222 | Increasing burden of liver disease in patients with HIV infection. <i>Lancet</i> , 2011 , 377, 1198-209 | 40 | 215 |
| 221 | Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. <i>Gut</i> , 2010 , 59, 1245-51 | 19.2 | 212 |

| | | | |
|-----|---|------|-----|
| 220 | Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. <i>Hepatology</i> , 2000 , 31, 49-53 | 11.2 | 198 |
| 219 | Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. <i>Gastroenterology</i> , 2008 , 134, 405-15 | 13.3 | 189 |
| 218 | Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017 , 153, 113-122 | 13.3 | 180 |
| 217 | 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018 , 68, 672-681 | 13.4 | 180 |
| 216 | Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. <i>Gastroenterology</i> , 2015 , 149, 1462-70 | 13.3 | 178 |
| 215 | Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 417-426 | 6.9 | 159 |
| 214 | Pregnancy and liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 933-45 | 13.4 | 131 |
| 213 | Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 900-909 | 18.8 | 129 |
| 212 | Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015 , 62, 533-40 | 13.4 | 124 |
| 211 | Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018 , 68, 1298-1307 | 11.2 | 121 |
| 210 | The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. <i>Hepatology</i> , 2012 , 55, 749-58 | 11.2 | 103 |
| 209 | Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. <i>Liver Transplantation</i> , 2008 , 14, 861-71 | 4.5 | 103 |
| 208 | The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019 , 70, 788-801 | 11.2 | 101 |
| 207 | Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. <i>Gut</i> , 2015 , 64, 1824-33 | 19.2 | 99 |
| 206 | Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. <i>Hepatology</i> , 2018 , 67, 514-523 | 11.2 | 96 |
| 205 | Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. <i>Journal of Hepatology</i> , 2017 , 67, 224-236 | 13.4 | 90 |
| 204 | Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. <i>Liver Transplantation</i> , 2006 , 12, 1496-503 | 4.5 | 89 |
| 203 | Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020 , 72, 539-557 | 13.4 | 88 |

| | | | |
|-----|---|------|----|
| 202 | Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016 , 65, 33-39 | 13.4 | 86 |
| 201 | Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. <i>Clinical Microbiology Reviews</i> , 2020 , 33, | 34 | 82 |
| 200 | Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. <i>Journal of Hepatology</i> , 2014 , 61, 228-34 | 13.4 | 80 |
| 199 | A183 SOFOSBUVIR-BASED ALL-ORAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION: INTEGRATED ANALYSIS OF FIVE CLINICAL STUDIES. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 318-319 | 0.5 | 78 |
| 198 | A180 IMPROVED RENAL LABORATORY PARAMETERS IN CHB PATIENTS TREATED WITH TAF COMPARED WITH TDF. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 313-314 | 0.5 | 78 |
| 197 | Hepatitis C virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 477-487 | 18.8 | 69 |
| 196 | Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". <i>American Journal of Transplantation</i> , 2014 , 14, 994-1002 | 8.7 | 68 |
| 195 | UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 647-62 | 6.1 | 66 |
| 194 | International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017 , 101, 945-955 | 1.8 | 63 |
| 193 | British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. <i>HIV Medicine</i> , 2010 , 11, 1-30 | 2.7 | 63 |
| 192 | Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 827-30 | 4.5 | 63 |
| 191 | Hepatitis B virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 466-476 | 18.8 | 62 |
| 190 | A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. <i>Tissue Antigens</i> , 2007 , 69, 227-35 | | 60 |
| 189 | Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 910-919 | 18.8 | 57 |
| 188 | Review of the neurological manifestations of hepatitis E infection. <i>Annals of Hepatology</i> , 2012 , 11, 618-622 | | 57 |
| 187 | The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. <i>Liver International</i> , 2013 , 33, 53-61 | 7.9 | 54 |
| 186 | Hepatitis associated with Chinese herbs. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 559-62 | 2.2 | 53 |
| 185 | Outcomes of pregnancy following liver transplantation: The King's College Hospital experience. <i>Liver Transplantation</i> , 2015 , 21, 1153-9 | 4.5 | 52 |

| | | | |
|-----|---|------|----|
| 184 | Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. <i>American Journal of Physiology - Cell Physiology</i> , 2021 , 320, C57-C65 | 5.4 | 51 |
| 183 | Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019 , 71, 660-665 | 13.4 | 50 |
| 182 | Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 152-166 | 18.8 | 49 |
| 181 | MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1B infection. <i>Journal of Hepatology</i> , 2017 , 66, S90-S91 | 13.4 | 47 |
| 180 | Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. <i>Transplantation</i> , 2007 , 84, 180-6 | 1.8 | 47 |
| 179 | Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. <i>Hepatology</i> , 2020 , 72, 42-57 | 11.2 | 46 |
| 178 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 441-453 | 18.8 | 45 |
| 177 | Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018 , 69, 603-607 | 13.4 | 44 |
| 176 | Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. <i>Hepatology</i> , 2011 , 54, 1538-46 | 11.2 | 43 |
| 175 | Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. <i>Clinical Infectious Diseases</i> , 2015 , 61, 883-91 | 11.6 | 42 |
| 174 | Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1331-1340 | 3.4 | 41 |
| 173 | International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017 , 101, 956-967 | 1.8 | 40 |
| 172 | Developing a donation after cardiac death risk index for adult and pediatric liver transplantation. <i>World Journal of Transplantation</i> , 2017 , 7, 203-212 | 2.3 | 40 |
| 171 | Transcriptomics in Interferon- α -treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression. <i>Neuropsychopharmacology</i> , 2016 , 41, 2502-11 | 8.7 | 39 |
| 170 | Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. <i>Gastroenterology</i> , 2014 , 146, 744-753.e3 | 13.3 | 37 |
| 169 | Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. <i>Journal of Hepatology</i> , 2019 , 71, 1099-1105 | 13.4 | 36 |
| 168 | Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. <i>Liver International</i> , 2013 , 33 Suppl 1, 137-50 | 7.9 | 35 |
| 167 | Alpha interferon for hepatitis C virus infection in haemophilic patients. <i>Haemophilia</i> , 1995 , 1, 54-8 | 3.3 | 34 |

| | | | |
|-----|---|------|----|
| 166 | Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2019 , 69, 959-973 | 11.2 | 33 |
| 165 | Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1363-75 | 6.1 | 31 |
| 164 | Genetic susceptibility to primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 1999 , 11, 603-6 | 2.2 | 31 |
| 163 | Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. <i>Psychoneuroendocrinology</i> , 2019 , 100, 276-285 | 5 | 31 |
| 162 | The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. <i>Clinical Infectious Diseases</i> , 2013 , 56, 951-60 | 11.6 | 30 |
| 161 | Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-alpha. <i>Hepatology</i> , 1992 , 15, 1002-6 | 11.2 | 29 |
| 160 | Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 957-966 | 6.1 | 28 |
| 159 | Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. <i>Journal of Hepatology</i> , 2018 , 68, 814-826 | 13.4 | 28 |
| 158 | British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , 2013 , 14 Suppl 4, 1-71 | 2.7 | 27 |
| 157 | Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 710-21 | 24.2 | 26 |
| 156 | Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. <i>Liver Transplantation</i> , 2013 , 19, 383-94 | 4.5 | 25 |
| 155 | Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. <i>BMC Infectious Diseases</i> , 2017 , 17, 722 | 4 | 24 |
| 154 | Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts. <i>Liver Transplantation</i> , 2015 , 21, 29-37 | 4.5 | 24 |
| 153 | Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation. <i>Gut</i> , 2006 , 55, 863-8 | 19.2 | 24 |
| 152 | Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 337-349 | 3.4 | 24 |
| 151 | Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. <i>Journal of Clinical Virology</i> , 2015 , 66, 33-7 | 14.5 | 23 |
| 150 | Reducing the Number of Measurements in Liver Point Shear-Wave Elastography: Factors that Influence the Number and Reliability of Measurements in Assessment of Liver Fibrosis in Clinical Practice. <i>Radiology</i> , 2018 , 287, 844-852 | 20.5 | 23 |
| 149 | HBSAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 886-893 | 3.4 | 23 |

| | | | |
|-----|--|------|----|
| 148 | Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2019 , 71, 1070 | 11.2 | 23 |
| 147 | Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. <i>Clinical Infectious Diseases</i> , 2017 , 65, 103-108 | 11.6 | 22 |
| 146 | Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. <i>Digestive and Liver Disease</i> , 2018 , 50, 944-953 | 3.3 | 21 |
| 145 | New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. <i>Gut</i> , 2012 , 61, 1647-52 | 19.2 | 21 |
| 144 | Does Donation After Cardiac Death Utilization Adversely Affect Hepatocellular Cancer Survival?. <i>Transplantation</i> , 2016 , 100, 1916-24 | 1.8 | 21 |
| 143 | The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. <i>Liver International</i> , 2017 , 37 Suppl 1, 7-12 | 7.9 | 20 |
| 142 | Reactivation of hepatitis B virus infection in patients with hematologic disorders. <i>Haematologica</i> , 2019 , 104, 435-443 | 6.6 | 20 |
| 141 | Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. <i>Journal of Hepatology</i> , 2017 , 67, 1348-1350 | 13.4 | 20 |
| 140 | Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?. <i>Lancet, The</i> , 2012 , 379, 2019-21 | 40 | 20 |
| 139 | Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 1033-9 | 9.5 | 19 |
| 138 | Palliative care in end-stage liver disease: Time to do better?. <i>Liver Transplantation</i> , 2018 , 24, 961-968 | 4.5 | 19 |
| 137 | STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015 , 62, 1246-55 | 13.4 | 19 |
| 136 | LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019 , 70, e130 | 13.4 | 18 |
| 135 | Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , 2018 , 67, 2113-2126 | 11.2 | 18 |
| 134 | Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. <i>Journal of Hepatology</i> , 2014 , 60, 1118-26 | 13.4 | 18 |
| 133 | A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B. <i>Journal of Hepatology</i> , 2017 , 66, S688-S689 | 13.4 | 18 |
| 132 | Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation. <i>Transplant International</i> , 2011 , 24, e93-6 | 3 | 18 |
| 131 | Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020 , 4, 8-20 | 6 | 18 |

| | | | |
|-----|--|------|----|
| 130 | Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2020 , | 6.9 | 17 |
| 129 | Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. <i>International Journal of Epidemiology</i> , 2017 , 46, 1391-1391h | 7.8 | 17 |
| 128 | Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. <i>Aids</i> , 2013 , 27, 1443-8 | 3.5 | 17 |
| 127 | Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <i>ELife</i> , 2019 , 8, | 8.9 | 17 |
| 126 | Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019 , 70, 24-32 | 13.4 | 17 |
| 125 | Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1641-1649.e6 | 6.9 | 16 |
| 124 | Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. <i>International Journal of STD and AIDS</i> , 2018 , 29, 414-417 | 1.4 | 15 |
| 123 | Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818786108 | 4.7 | 15 |
| 122 | Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 805-813 | 18.8 | 15 |
| 121 | Liver transplantation in human immunodeficiency virus-positive patients. <i>Liver Transplantation</i> , 2011 , 17, 881-90 | 4.5 | 15 |
| 120 | Development and validation of an efficient in-house real-time reverse transcription polymerase chain reaction assay for the quantitative detection of serum hepatitis delta virus RNA in a diverse South London population. <i>Journal of Virological Methods</i> , 2012 , 184, 55-62 | 2.6 | 14 |
| 119 | Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 231-235 | 3.4 | 14 |
| 118 | Hepatitis E--an unexpected problem at home. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 253 | 2.4 | 13 |
| 117 | Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020 , 72, 431-440 | 13.4 | 13 |
| 116 | Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , 2008 , 13, 23-30 | 1.6 | 13 |
| 115 | Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2017 , 66, S25 | 13.4 | 12 |
| 114 | Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019 , 79, 503-512 | 18.9 | 12 |
| 113 | Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. <i>Liver International</i> , 2014 , 34, 12-5 | 7.9 | 12 |

| | | | |
|-----|---|------|----|
| 112 | The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2021 , | 40 | 12 |
| 111 | Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 32-44 | 18.8 | 12 |
| 110 | The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19 | 3.4 | 12 |
| 109 | The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 204-214 | 6.1 | 11 |
| 108 | Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 659-71 | 6.1 | 11 |
| 107 | Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx067 | 1 | 11 |
| 106 | Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions. <i>Journal of Health Psychology</i> , 2018 , 23, 1405-1414 | 3.1 | 10 |
| 105 | Patient perception of skin-cancer prevention and risk after liver transplantation. <i>Clinical and Experimental Dermatology</i> , 2013 , 38, 851-6 | 1.8 | 10 |
| 104 | Role of liver transplantation in human immunodeficiency virus positive patients. <i>World Journal of Gastroenterology</i> , 2015 , 21, 12311-21 | 5.6 | 10 |
| 103 | Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). <i>Mitochondrion</i> , 2021 , 57, 119-130 | 4.9 | 10 |
| 102 | Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. <i>Journal of Hepatology</i> , 2020 , 72, 1097-1104 | 13.4 | 9 |
| 101 | Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. <i>Journal of Infectious Diseases</i> , 2014 , 209, 734-8 | 7 | 9 |
| 100 | The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome?. <i>Transplant International</i> , 2013 , 26, 1070-9 | 3 | 9 |
| 99 | Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019 , 39, 1837-1844 | 7.9 | 8 |
| 98 | Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). <i>Journal of Viral Hepatitis</i> , 2018 , 25, 118-125 | 3.4 | 8 |
| 97 | Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. <i>Journal of Hepatology</i> , 2018 , 68, S67-S68 | 13.4 | 8 |
| 96 | The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. <i>Anaesthesia</i> , 2007 , 62, 282-5 | 6.6 | 8 |
| 95 | Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. <i>Journal of Hepatology</i> , 2003 , 39 Suppl 1, S116-23 | 13.4 | 8 |

| | | | |
|----|--|------|---|
| 94 | Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. <i>Infection</i> , 2017 , 45, 215-220 | 5.8 | 7 |
| 93 | Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation. <i>Liver Transplantation</i> , 2020 , 26, 811-822 | 4.5 | 7 |
| 92 | Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019 , 9, 10529 | 4.9 | 7 |
| 91 | CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response. <i>Clinical Transplantation</i> , 2014 , 28, 569-78 | 3.8 | 7 |
| 90 | Do laparoscopy and intraoperative ultrasound have a role in the assessment of patients with end-stage liver disease and hepatocellular carcinoma for liver transplantation?. <i>Transplantation Proceedings</i> , 2007 , 39, 1474-6 | 1.1 | 7 |
| 89 | Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. <i>American Journal of Transplantation</i> , 2016 , 16, 679-87 | 8.7 | 7 |
| 88 | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. <i>Kidney International Reports</i> , 2019 , 4, 257-266 | 4.1 | 7 |
| 87 | Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy. <i>Clinical Infectious Diseases</i> , 2021 , 72, 2029-2031 | 11.6 | 7 |
| 86 | Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , 2008 , 13 Suppl 1, 23-30 | 1.6 | 7 |
| 85 | Management of chronic hepatitis B before and after liver transplantation. <i>Frontline Gastroenterology</i> , 2018 , 9, 79-84 | 2.6 | 6 |
| 84 | Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything. <i>Journal of Hepatology</i> , 2017 , | 13.4 | 6 |
| 83 | High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies. <i>Journal of Hepatology</i> , 2016 , 64, S759 | 13.4 | 6 |
| 82 | Probability of HBsAg loss after nucleo(s)ide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , 2022 , | 13.4 | 6 |
| 81 | Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation. <i>World Journal of Hepatology</i> , 2017 , 9, 884-895 | 3.4 | 6 |
| 80 | Hepatitis B in sub-Saharan Africa-How many patients need therapy?. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 560-567 | 3.4 | 6 |
| 79 | Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients. <i>Journal of Hepatology</i> , 2016 , 64, S185-S186 | 13.4 | 6 |
| 78 | Severe alcohol-related liver disease admissions post-COVID-19 lockdown: canary in the coal mine?. <i>Frontline Gastroenterology</i> , 2021 , 12, 354-355 | 2.6 | 6 |
| 77 | Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018 , 66, 1339-1345 | 5.6 | 6 |

| | | | |
|----|---|------|---|
| 76 | Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017 , 177, 637-644 | 4 | 5 |
| 75 | Will we need novel combinations to cure HBV infection?. <i>Liver International</i> , 2020 , 40 Suppl 1, 35-42 | 7.9 | 5 |
| 74 | Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. <i>Digestive and Liver Disease</i> , 2018 , 50, 113-123 | 3.3 | 5 |
| 73 | Delineating the global challenges of hepatitis B virus infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 372-373 | 18.8 | 5 |
| 72 | Treatment of chronic hepatitis C virus infection after liver transplantation. <i>Digestive and Liver Disease</i> , 2013 , 45 Suppl 5, S349-54 | 3.3 | 5 |
| 71 | Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017 , 16, 375-381 | 3.1 | 5 |
| 70 | Familial primary biliary cirrhosis and autoimmune cholangitis. <i>Digestive and Liver Disease</i> , 2002 , 34, 50-2 | 3.3 | 5 |
| 69 | A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure. <i>Journal of Hepatology</i> , 2021 , 75, 424-434 | 13.4 | 5 |
| 68 | A case of HBV-induced liver failure in the REEF-2 Phase 2 trial: Implications for finite treatment strategies in HBV 'cure'.. <i>Journal of Hepatology</i> , 2022 , | 13.4 | 5 |
| 67 | Successful liver transplantation for drug-induced vanishing bile duct syndrome. <i>BMJ Case Reports</i> , 2020 , 13, | 0.9 | 4 |
| 66 | Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 80-87 | 3.4 | 4 |
| 65 | Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. <i>Blood</i> , 2011 , 118, 2232-2232 | 2.2 | 4 |
| 64 | Differential effect of interferon-alpha treatment on AEA and 2-AG levels. <i>Brain, Behavior, and Immunity</i> , 2020 , 90, 248-258 | 16.6 | 4 |
| 63 | The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2020 , 19, 362-369 | 1 | 4 |
| 62 | FRI-159-Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?. <i>Journal of Hepatology</i> , 2019 , 70, e458 | 13.4 | 3 |
| 61 | PS-181-Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes : Implications for global elimination. <i>Journal of Hepatology</i> , 2019 , 70, e111-e112 | 13.4 | 3 |
| 60 | 905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAIVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , 2013 , 58, S373 | 13.4 | 3 |
| 59 | Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study. <i>Gastroenterology</i> , 2017 , 152, S1061 | 13.3 | 3 |

| | | | |
|----|--|------|---|
| 58 | Cutaneous side-effects of antihepatitis C treatment: the U.K. experience. <i>British Journal of Dermatology</i> , 2015 , 172, 292-3 | 4 | 3 |
| 57 | P47 De-novo antiviral therapy with nucleos(t)ide analogues in real-life patients with chronic hepatitis B infection: comparison of virological responses between lamivudine + adefovir vs entecavir vs tenofovir therapy. <i>Gut</i> , 2011 , 60, A22-A23 | 19.2 | 3 |
| 56 | Concentration Monitoring of Plasma Ribavirin: Validation of a Liquid Chromatography-Mass Spectrometric Method and Clinical Sample Collection. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 50-8 | 3.2 | 3 |
| 55 | The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C. <i>Antiviral Therapy</i> , 2018 , 23, 539-542 | 1.6 | 3 |
| 54 | Hepatitis C in the EU: setting the terms for elimination. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 314-315 | 18.8 | 2 |
| 53 | Strain elastography for noninvasive assessment of liver fibrosis: A prospective study with histological comparison. <i>Ultrasound</i> , 2019 , 27, 262-271 | 1.3 | 2 |
| 52 | PS-055-The markers of HBV transcriptional activity-HBcrAg and pre-genomic HBV DNA during antiviral therapy with nucleos (t)ide analogue help to predict optimal timing of therapy withdrawal. <i>Journal of Hepatology</i> , 2019 , 70, e33-e34 | 13.4 | 2 |
| 51 | Faldaprevir for the treatment of genotype-1 hepatitis C virus. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 277-88 | 4.2 | 2 |
| 50 | Hope for non-responders with hepatitis C virus and cirrhosis. <i>Lancet Infectious Diseases</i> , 2015 , 15, 363-5 | 25.5 | 2 |
| 49 | Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'". <i>Journal of Hepatology</i> , 2018 , 68, 864-866 | 13.4 | 2 |
| 48 | Antiviral treatment for hepatitis C: rebalancing cost, affordability, and availability. <i>The Lancet Global Health</i> , 2019 , 7, e1150-e1151 | 13.6 | 2 |
| 47 | PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019 , 70, e110 | 13.4 | 2 |
| 46 | Predictors of graft and patient survival in subjects undergoing transplantation for hepatitis C virus infection. <i>Liver Transplantation</i> , 2010 , 16, 536-7 | 4.5 | 2 |
| 45 | English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 168-181 | 6.1 | 2 |
| 44 | Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2013 , 108, S145 | 0.7 | 2 |
| 43 | Towards the elimination and eradication of hepatitis B. <i>Journal of Virus Eradication</i> , 2015 , 1, 4-12 | 2.8 | 2 |
| 42 | Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa. <i>Journal of Infectious Diseases</i> , 2021 , | 7 | 2 |
| 41 | Patterns and prediction of liver injury with persistent cholestasis in survivors of severe SARS-CoV-2 infection. <i>Journal of Infection</i> , 2021 , 82, e11-e13 | 18.9 | 2 |

| | | | |
|----|--|------|---|
| 40 | Hepatitis B cure: How and when. <i>Liver International</i> , 2021 , 41 Suppl 1, 24-29 | 7.9 | 2 |
| 39 | The road map toward an hepatitis C virus-free transplant population. <i>American Journal of Transplantation</i> , 2018 , 18, 2409-2416 | 8.7 | 2 |
| 38 | Controlling hepatitis C with simeprevir. <i>Lancet Infectious Diseases, The</i> , 2015 , 15, 2-4 | 25.5 | 1 |
| 37 | Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1139-1150 | 3.4 | 1 |
| 36 | Current and future directions of management of hepatitis B: steps toward a cure. <i>Future Virology</i> , 2018 , 13, 189-209 | 2.4 | 1 |
| 35 | Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 224-225 | 18.8 | 1 |
| 34 | Liver abnormalities in the immunosuppressed. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2013 , 27, 597-618 | 2.5 | 1 |
| 33 | Hepatitis C treatment: interferon free or interferon free?. <i>Lancet, The</i> , 2013 , 381, 2063-5 | 40 | 1 |
| 32 | Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations. <i>Gut</i> , 2021 , 70, 629-630 | 19.2 | 1 |
| 31 | Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 168-176 | 3.4 | 1 |
| 30 | Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , 2016 , 15, 512-23 | 3.1 | 1 |
| 29 | Treatment of hepatitis C infection. Review underplayed important public health issues. <i>BMJ: British Medical Journal</i> , 1999 , 319, 450-1 | | 0 |
| 28 | Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action". <i>Journal of Hepatology</i> , 2020 , 72, 585-586 | 13.4 | 0 |
| 27 | A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2021 , 53, 207-214 | 1.1 | 0 |
| 26 | Global elimination of hepatitis C: a warning from the data.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 380-381 | 18.8 | 0 |
| 25 | Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction. <i>Transplantation Direct</i> , 2020 , 6, e528 | 2.3 | |
| 24 | Treatment of Genotype 3 Chronic Hepatitis C Virus Infection. <i>Clinical Medicine Insights Therapeutics</i> , 2017 , 9, 1179559X1769433 | | 0 |
| 23 | PWE-037 Reliability of Arfi Shear Velocity Cut-Off for Diagnosis of Cirrhosis in Chronic Hepatitis C: A "Real World" Two Centre Simultaneous Biopsy-Controlled Study in The UK. <i>Gut</i> , 2016 , 65, A157.1-A157 | 19.2 | |

- 22 Viral Hepatitis and Hemophilia **2014**, 263-271
- 21 Maintaining clinical governance when giving telephone advice. *Frontline Gastroenterology*, **2013**, 4, 270-273
- 20 PTH-178 Who Calls the Liver Registrar at King's? *Gut*, **2013**, 62, A283.3-A284 19.2
- 19 Massive gastrointestinal bleed in a patient with primary sclerosing cholangitis. *Gastroenterology*, **2011**, 140, e7-8 13.3
- 18 P67 Switch to other nucleos(t)ide analogues therapy in chronic hepatitis B cohort on long-term de-novo combination therapy with lamivudine plus adefovir: efficacy and safety. *Gut*, **2011**, 60, A31-A31 19.2
- 17 P77 A Pharmacist delivered stratified conversion protocol from Hepatitis B Immunoglobulin (HBIG) to tenofovir or entecavir is efficacious, safe and cost-effective for prevention of recurrence of Hepatitis B virus (HBV) in Liver Transplant (LT) recipients. *Gut*, **2011**, 60, A35-A36 19.2
- 16 The UK experience of liver transplantation in patients receiving opiate replacement therapy. *Gut*, **2011**, 60, A58-A59 19.2
- 15 P100 Liver transplantation (LT) results in reduced recipient Natural Killer (NK) cell activation with associated down regulation of activating receptors NKp30 and NKp46 but not NKG2D. *Gut*, **2011**, 60, A46-A47 19.2
- 14 PTU-060 Primary sclerosing cholangitis post liver transplantation: the impact of inflammatory bowel disease. *Gut*, **2010**, 59, A73.1-A73 19.2
- 13 PMO-178 The significance of viral and serological markers in predicting liver disease severity in e-Ag negative hepatitis b virus infection. *Gut*, **2012**, 61, A146.1-A146 19.2
- 12 PTU-059 Hepatitis C virus infection abrogates the effect of liver transplantation on NK cell activation. *Gut*, **2012**, 61, A208.1-A208 19.2
- 11 PTU-016a Functional defects in circulating monocytes may contribute to susceptibility to infection in alcoholic hepatitis. *Gut*, **2012**, 61, A189.2-A190 19.2
- 10 Hepatitis C and bleeding disorders in Europe. *The Journal of Haemophilia Practice*, **2018**, 5, 50-65 0.2
- 9 Hepatitis and Hemophilia 486-493
- 8 EASL Recognition Award Recipient 2020: Prof. Patrick Marcellin. *Journal of Hepatology*, **2020**, 73, 482-483 3.4
- 7 PTH-107 Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance. *Gut*, **2016**, 65, A271.2-A272 19.2
- 6 Hepatitis C: Treatment **2019**, 454-469
- 5 Reply. *Hepatology*, **2021**, 73, 870-871 11.2

4 Current Management of Patients with HCV Genotype 5 or 6 **2021**, 129-140

3 Unmet Needs in Clinical Research Hepatitis B **2021**, 51-71

2 Patient access. How to wipe out a growing killer. *The Health Service Journal*, **2011**, 121, 20-2

1 Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. *Annals of Hepatology*, **2017**, 16, 375-381

3.1